Halozyme Therapeutics (HALO) Short Interest Ratio & Short Volume $53.00 +0.87 (+1.67%) (As of 10/11/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Halozyme Therapeutics Short Interest DataHalozyme Therapeutics (HALO) has a short interest of 9.85 million shares, representing 7.86% of the float (the number of shares available for trading by the public). This marks a 2.18% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.2, indicating that it would take 7.2 days of the average trading volume of 1.29 million shares to cover all short positions.Current Short Interest9,850,000 sharesPrevious Short Interest9,640,000 sharesChange Vs. Previous Month+2.18%Dollar Volume Sold Short$563.81 millionShort Interest Ratio7.2 Days to CoverLast Record DateSeptember 30, 2024Outstanding Shares127,274,000 sharesFloat Size125,300,000 sharesShort Percent of Float7.86%Today's Trading Volume861,732 sharesAverage Trading Volume1,294,586 sharesToday's Volume Vs. Average67% Short Selling Halozyme Therapeutics? Sign up to receive the latest short interest report for Halozyme Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartHALO Short Interest Over TimeHALO Days to Cover Over TimeHALO Percentage of Float Shorted Over Time Ad Brownstone ResearchBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate Halozyme Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/30/20249,850,000 shares $563.81 million +2.2%7.9%7.2 $57.24 9/15/20249,640,000 shares $600.57 million -4.0%7.7%7.4 $62.30 8/31/202410,040,000 shares $641.05 million +3.8%8.0%7.6 $63.85 8/15/20249,670,000 shares $571.50 million +8.0%7.7%7.2 $59.10 7/31/20248,950,000 shares $494.58 million +2.8%7.1%6.8 $55.26 7/15/20248,710,000 shares $457.71 million -3.4%6.9%7 $52.55 Get the Latest News and Ratings for HALO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 6/30/20249,020,000 shares $472.29 million -3.1%7.2%7.5 $52.36 6/15/20249,310,000 shares $460.85 million +8.8%7.4%8.4 $49.50 5/31/20248,560,000 shares $379.12 million No Change6.8%8.1 $44.29 5/15/20248,560,000 shares $392.22 million +1.8%6.8%8.7 $45.82 4/30/20248,410,000 shares $320.42 million +2.1%6.7%8.2 $38.10 4/15/20248,240,000 shares $319.05 million +4.4%6.6%7.8 $38.72 3/31/20247,890,000 shares $320.97 million -3.8%6.3%6.1 $40.68 3/15/20248,200,000 shares $335.05 million +1.5%6.5%6.1 $40.86 2/29/20248,080,000 shares $321.66 million +5.6%6.4%5.9 $39.81 2/15/20247,650,000 shares $274.71 million +0.1%6.1%5.7 $35.91 1/31/20247,640,000 shares $258.61 million +6.6%5.8%5.7 $33.85 1/15/20247,170,000 shares $246.86 million -2.5%5.5%5.7 $34.43 12/31/20237,350,000 shares $271.66 million -2.0%5.6%7 $36.96 12/15/20237,500,000 shares $292.65 million +5.2%5.7%8 $39.02 11/30/20237,130,000 shares $275.29 million +2.3%5.5%7.9 $38.61 11/15/20236,970,000 shares $274.20 million +5.9%5.3%8 $39.34 10/31/20236,580,000 shares $222.86 million -0.5%5.0%7.8 $33.87 10/15/20236,610,000 shares $241.60 million +2.3%5.1%7.8 $36.55 9/30/20236,460,000 shares $246.77 million -5.6%5.0%6.9 $38.20 9/15/20236,840,000 shares $268.26 million No Change5.2%6.9 $39.22 8/31/20236,840,000 shares $291.11 million -6.3%5.2%6.6 $42.56 8/15/20237,300,000 shares $321.35 million -3.2%5.6%7 $44.02 7/31/20237,540,000 shares $323.92 million +7.7%5.8%6.6 $42.96 7/15/20237,000,000 shares $267.54 million +5.4%5.4%5.8 $38.22 6/30/20236,640,000 shares $239.50 million -1.5%5.1%5.7 $36.07 6/15/20236,740,000 shares $230.24 million -3.2%5.2%5.1 $34.16 5/31/20236,960,000 shares $225.71 million +5.6%5.3%4.5 $32.43 5/15/20236,590,000 shares $223.40 million +2.3%5.1%4 $33.90 4/30/20236,440,000 shares $206.92 million -2.0%4.8%4.1 $32.13 4/15/20236,570,000 shares $234.22 million +0.5%4.9%4.3 $35.65 3/31/20236,540,000 shares $249.76 million -0.9%4.9%4.1 $38.19 3/15/20236,600,000 shares $264.33 million -4.2%4.9%4.5 $40.05 2/28/20236,890,000 shares $330.65 million +1.8%5.2%5.6 $47.99 2/15/20236,770,000 shares $333.08 million -3.4%5.1%5.6 $49.20Bill Gates’s Next Big AI Bet: Stargate (Ad)In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate 1/31/20237,010,000 shares $362.91 million -19.2%5.2%5.5 $51.77 1/15/20238,670,000 shares $436.45 million -4.8%6.5%6.8 $50.34 12/30/20229,110,000 shares $518.36 million -3.9%6.8%7.9 $56.90 12/15/20229,480,000 shares $540.64 million -2.0%7.1%8 $57.03 11/30/20229,670,000 shares $553.70 million -4.6%7.2%7.9 $57.26 11/15/202210,140,000 shares $547.76 million -6.3%7.6%8.7 $54.02 10/31/202210,820,000 shares $517.30 million -5.6%7.9%8.3 $47.81 10/15/202211,460,000 shares $506.19 million -5.4%8.4%8.7 $44.17 9/30/202212,110,000 shares $478.83 million +11.6%8.9%9.1 $39.54 9/15/202210,850,000 shares $459.28 million +1.6%8.0%7.6 $42.33 8/31/202210,680,000 shares $435.00 million +18.9%7.8%7.9 $40.73 8/15/20228,980,000 shares $386.95 million -1.4%6.6%6.7 $43.09 7/31/20229,110,000 shares $445.48 million +2.4%6.7%7.7 $48.90 7/15/20228,900,000 shares $437.52 million +9.1%6.9%7.6 $49.16 6/30/20228,160,000 shares $359.04 million -3.8%6.3%7.1 $44.00 6/15/20228,480,000 shares $378.46 million +1.3%6.5%8 $44.63 5/31/20228,370,000 shares $384.85 million +5.4%6.1%8.5 $45.98 5/15/20227,940,000 shares $320.93 million -1.2%5.8%8.3 $40.42 4/30/20228,040,000 shares $320.80 million +8.8%5.9%9.1 $39.90 4/15/20227,390,000 shares $312.38 million +3.5%5.4%8.3 $42.27 3/31/20227,140,000 shares $284.74 million +3.9%5.2%7.8 $39.88 3/15/20226,870,000 shares $242.92 million +5.5%5.1%7.8 $35.36 2/28/20226,510,000 shares $230.91 million +3.5%4.8%6.7 $35.47 2/15/20226,290,000 shares $216.56 million -0.6%4.6%6.3 $34.43 1/31/20226,330,000 shares $219.08 million +1.8%4.6%6.5 $34.61 1/15/20226,220,000 shares $221.18 million -4.6%N/A6.6 $35.56 12/31/20216,520,000 shares $262.17 million +0.2%4.7%7.4 $40.21 12/15/20216,510,000 shares $240.41 million +2.5%4.7%7.3 $36.93 11/30/20216,350,000 shares $208.79 million +6.0%4.6%8 $32.88 11/15/20215,990,000 shares $228.76 million -6.3%4.3%7.9 $38.19 10/29/20216,390,000 shares $243.27 million +6.2%4.6%8.3 $38.07 10/15/20216,020,000 shares $227.32 million -2.1%4.3%7.9 $37.76 9/30/20216,150,000 shares $250.18 million +7.3%4.4%8 $40.68 9/15/20215,730,000 shares $236.36 million -3.9%4.1%7.8 $41.25 8/31/20215,960,000 shares $250.26 million +5.1%4.3%7.7 $41.99 8/13/20215,670,000 shares $235.13 million -0.9%4.1%7 $41.47 7/30/20215,720,000 shares $236.41 million -10.5%4.1%6.4 $41.33 7/15/20216,390,000 shares $274.13 million -1.2%4.6%7.2 $42.90 6/30/20216,470,000 shares $293.80 million No Change4.6%7 $45.41 6/15/20216,470,000 shares $277.89 million -5.6%4.6%6.3 $42.95 5/28/20216,850,000 shares $283.66 million -4.5%4.9%6.7 $41.41 5/14/20217,170,000 shares $299.49 million -3.5%5.1%5.3 $41.77 4/30/20217,430,000 shares $381.23 million +5.5%5.3%5.5 $51.31 4/15/20217,040,000 shares $323.49 million -9.4%5.0%5.1 $45.95 3/31/20217,770,000 shares $319.27 million -6.2%5.6%5.4 $41.09 3/15/20218,280,000 shares $367.38 million -33.3%6.3%5.9 $44.37 2/26/202112,420,000 shares $587.59 million -13.9%9.4%8.7 $47.31 2/12/202114,430,000 shares $717.75 million -5.1%10.9%10.9 $49.74 1/29/202115,200,000 shares $728.23 million -0.3%11.6%8.8 $47.91 1/15/202115,250,000 shares $717.51 million +2.7%11.7%8.1 $47.05Bill Gates’s Next Big AI Bet: Stargate (Ad)In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate 12/31/202014,850,000 shares $632.46 million -4.0%11.4%7.7 $42.59 12/15/202015,460,000 shares $647.00 million -7.0%11.8%8.1 $41.85 11/30/202016,630,000 shares $669.02 million +13.9%12.7%8.7 $40.23 11/15/202014,600,000 shares $567.21 million +8.6%11.2%8 $38.85 10/30/202013,450,000 shares $388.57 million -10.2%10.3%9.6 $28.89 10/15/202014,980,000 shares $428.28 million +2.4%11.4%13.9 $28.59 9/30/202014,630,000 shares $384.48 million -4.2%N/A15 $26.28 9/15/202015,270,000 shares $420.38 million -1.0%11.6%13.9 $27.53 8/31/202015,430,000 shares $447.47 million -3.9%11.7%13.9 $29.00 8/14/202016,050,000 shares $447.63 million -0.7%12.2%13.5 $27.89 7/31/202016,170,000 shares $439.66 million -3.4%12.7%12.3 $27.19 7/15/202016,730,000 shares $454.89 million +2.3%13.2%11.6 $27.19 6/30/202016,350,000 shares $422.16 million +0.8%12.9%11.2 $25.82 6/15/202016,220,000 shares $375.49 million +0.7%12.8%11.5 $23.15 5/29/202016,110,000 shares $390.99 million +2.5%12.7%9.8 $24.27 5/15/202015,720,000 shares $373.82 million +1.6%12.4%8.7 $23.78 4/30/202015,480,000 shares $350.70 million +9.4%12.0%8.7 $22.66 4/15/202014,150,000 shares $251.30 million +1.1%11.0%8 $17.76 3/31/202013,990,000 shares $327.65 million -0.8%10.8%7.5 $23.42 3/13/202014,109,100 shares $253.68 million +1.7%10.9%7.5 $17.98 2/28/202013,870,000 shares $233.29 million +7.9%10.7%8.8 $16.82 2/14/202012,850,000 shares $249.68 million -1.0%9.9%8.3 $19.43 1/31/202012,980,000 shares $274.79 million +4.7%10.2%7.2 $21.17 1/15/202012,400,000 shares $245.89 million -0.2%9.7%6.6 $19.83 12/31/201912,430,000 shares $237.04 million -0.9%9.1%7.2 $19.07 HALO Short Interest - Frequently Asked Questions What is Halozyme Therapeutics' current short interest? Short interest is the volume of Halozyme Therapeutics shares that have been sold short but have not yet been closed out or covered. As of September 30th, traders have sold 9,850,000 shares of HALO short. 7.86% of Halozyme Therapeutics' shares are currently sold short. Learn More on Halozyme Therapeutics' current short interest. What is a good short interest ratio for Halozyme Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HALO shares currently have a short interest ratio of 7.0. Learn More on Halozyme Therapeutics's short interest ratio. Which institutional investors are shorting Halozyme Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Halozyme Therapeutics: Concourse Financial Group Securities Inc., Oak Hill Wealth Advisors LLC, Susquehanna International Group LLP, Torno Capital LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Halozyme Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.86% of Halozyme Therapeutics' floating shares are currently sold short. Is Halozyme Therapeutics' short interest increasing or decreasing? Halozyme Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 9,850,000 shares, an increase of 2.2% from the previous total of 9,640,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Halozyme Therapeutics' float size? Halozyme Therapeutics currently has issued a total of 126,680,000 shares. Some of Halozyme Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Halozyme Therapeutics currently has a public float of 125,300,000 shares. How does Halozyme Therapeutics' short interest compare to its competitors? 7.86% of Halozyme Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Halozyme Therapeutics: Iovance Biotherapeutics, Inc. (24.26%), Twist Bioscience Co. (14.85%), Relay Therapeutics, Inc. (9.24%), Adaptive Biotechnologies Co. (6.72%), Allogene Therapeutics, Inc. (28.20%), Fate Therapeutics, Inc. (12.45%), Kodiak Sciences Inc. (3.16%), Biogen Inc. (1.97%), United Therapeutics Co. (5.12%), Incyte Co. (3.57%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.04 billion), AppLovin Co. ($2.69 billion), Nu Holdings Ltd. ($2.64 billion), Paychex, Inc. ($2.61 billion), Cencora, Inc. ($2.30 billion), Aptiv PLC ($2.09 billion), Moderna, Inc. ($2.09 billion), Tractor Supply ($2.04 billion), Coinbase Global, Inc. ($1.97 billion), and International Paper ($1.95 billion). View all of the most shorted stocks. What does it mean to sell short Halozyme Therapeutics stock? Short selling HALO is an investing strategy that aims to generate trading profit from Halozyme Therapeutics as its price is falling. HALO shares are trading up $0.87 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Halozyme Therapeutics? A short squeeze for Halozyme Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HALO, which in turn drives the price of the stock up even further. How often is Halozyme Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HALO, twice per month. The most recent reporting period available is September, 30 2024. More Short Interest Resources from MarketBeat Related Companies: IOVA Short Interest TWST Short Interest RLAY Short Interest ADPT Short Interest ALLO Short Interest FATE Short Interest KOD Short Interest BIIB Short Interest UTHR Short Interest INCY Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:HALO) was last updated on 10/12/2024 by MarketBeat.com Staff From Our PartnersAI Expert Reveals New PickYour Financial Planner Won't Tell You About This Investment Strategy Silicon Valley insider Jeff Brown has ...Brownstone Research | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe Great Crypto Frenzy 2.0 is About to StartBitcoin’s Final Bull Run: Three Altcoins to Get Into NOW! “Crypto Whisperer” Ian King is calling it: due to...Banyan Hill Publishing | SponsoredNotice: Major payout due November 19th - are you on the list?On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's p...Behind the Markets | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
